DIM-C-pPhOH

DIM-C-pPhOH is a nuclear receptor 4A1 (NR4A1) antagonist. DIM-C-pPhOH inhibits cancer cell growth and mTOR signaling, induce apoptosis and cellular stress. DIM-C-pPhOH reduces cell proliferation with IC50 values of 13.6 μM and 13.0 μM for ACHN cells and 786-O cells, respectively[1].

Signaling Pathways >> Apoptosis >> Apoptosis

Research Areas >> Cancer

Nuclear receptor 4A1 (NR4A1)[1]

DIM-C-pPhOH (7.5-20 μM; 24 hours; ACHN and 786-O cells) treatment significantly decreases cell proliferation[1]. DIM-C-pPhOH (20 μM; 24 hours; ACHN and 786-O cells) treatment induces Annexin V staining in ACHN and 786-O cells, confirming that DIM-C-pPhOH induce apoptosis, and also induces cleavage of caspases 7 and 8[1]. DIM-C-pPhOH (15-20 μM; 24 hours; ACHN and 786-O cells) treatment inhibits NR4A1-regulated expression of survivin, bcl-2 and EGFR in ACHN and 786-O cells. And also induces sestrin 2, activates AMPKα and inhibits activation of mTOR and downstream kinases[1]. DIM-C-pPhOH decreases expression of β1-integrin protein and mRNA and β1-integrin-dependent responses in MCF7, MDA-MB-231, and SKBR3 cells and also inhibits migration of the latter two cell lines[2]. Cell Proliferation Assay[1] Cell Line: ACHN and 786-O cells Concentration: 7.5 μM, 15 μM, 20 μM Incubation Time: 24 hours Result: Significantly decreased cell proliferation. Apoptosis Analysis[1] Cell Line: ACHN and 786-O cells Concentration: 20 μM Incubation Time: 24 hours Result: Induced apoptosis in ACHN and 786-O cells. Western Blot Analysis[1] Cell Line: ACHN and 786-O cells Concentration: 15 μM, 20 μM Incubation Time: 24 hours Result: Inhibited NR4A1-regulated expression of survivin, bcl-2 and EGFR in ACHN and 786-O cells. And also induced sestrin 2, activated AMPKα and inhibited activation of mTOR and downstream kinases.

DIM-C-pPhOH (30 mg/kg; oral gavage; daily; for 50 days; male athymic nude mice) treatment results in a significant inhibition of tumor growth[1]. Animal Model: Male athymic nude mice (aged 6-7 weeks) injected with ACHN cells[1] Dosage: 30 mg/kg/day Administration: Oral gavage; daily; for 50 days Result: Resulted in a significant inhibition of tumor growth.

[1]. Hedrick E, et al. Nuclear Receptor 4A1 (NR4A1) as a Drug Target for Renal Cell Adenocarcinoma. PLoS One. 2015 Jun 2;10(6):e0128308.

[2]. Hedrick E, et al. NR4A1 Antagonists Inhibit β1-Integrin-Dependent Breast Cancer Cell Migration. Mol Cell Biol. 2016 Apr 15;36(9):1383-94.